Dapagliflozin crystal form and preparation method and use thereof

US10464915B2 · kind B2 · utility

Assignee

• JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD · CN

Inventors

• Xiang Li · Beijing, CN
• Lei He · Moraga, US
• Jun Yu · Sha Tin, CN
• Jinjia Wang · Shanghai, CN
• Zuyin Du · 安丰镇, CN

Key dates

• Filing date: May 22, 2017
• Grant date: Nov 5, 2019
• Expiry date: May 22, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(β-D-glucopyranose-1-yl)-4′-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.